



# SERIOUS SHORTAGE PROTOCOL (SSP)

Reference Number: SSP04

Version 1

This SSP applies to the following medicine:

<b>Name of medicine (including strength and formulation)</b>	Haloperidol (Serenace®) 500 microgram capsules—prescribed as Serenace® 500 microgram capsules or Haloperidol 500 microgram capsules
<b>Legal category</b>	POM

## 1. Details of medication to be supplied under this SSP

<b>Name of medicine (including formulation and strength) to be supplied</b>	Haloperidol 500 microgram tablets
<b>Quantity of this formulation (if applicable)</b>	Total quantity supplied under this protocol to be equivalent to the number of days prescribed on original prescription  For every 500 microgram haloperidol (Serenace®) capsule, the following quantity must be supplied in accordance with this protocol: <ul style="list-style-type: none"><li>• 1 x 500 microgram haloperidol tablet</li></ul>
<b>Substitution results in a change to whether the use is licenced</b>	No

### Scope for which this Serious Shortage Protocol (SSP) applies

<b>The SSP applies to the following parts of the UK</b>	England and Wales.
---	--------------------

### Clinical situation to which this Serious Shortage Protocol (SSP) applies

<b>Scope of SSP</b>	All NHS and private prescriptions.
<b>Criteria for inclusion</b>	<ul style="list-style-type: none"><li>• The patient presents with a valid prescription (meeting the requirements of the Human Medicines Regulations)</li></ul>

	<p>2012) for haloperidol (Serenace®) 500 microgram capsules, whether written generically or by brand.</p> <ul style="list-style-type: none"> <li>• The patient/carer consents to receiving the medicine supplied under this SSP.</li> <li>• All patients aged 18 years of age or above.</li> </ul>
<b>Criteria for exclusion</b>	<ul style="list-style-type: none"> <li>• All patients aged under 18 years old.</li> <li>• The patient presents with a prescription for a medicine other than haloperidol (Serenace®) 500 microgram capsules.</li> <li>• Known previous hypersensitivity or severe adverse reaction to haloperidol tablets or their excipients.</li> <li>• The patient presents a prescription which is not valid.</li> <li>• The patient/carer does not consent to receiving the medicine(s) supplied under this SSP.</li> <li>• Where the pharmacist, using their professional judgement, determines that the patient is not suitable to receive the alternative medicine under this SSP.</li> <li>• Where the pharmacist is aware that the patient has been hospitalised in an inpatient mental health unit within the last 6 months.</li> <li>• The patient has a specific requirement for capsules (e.g. capsules contents are opened and mixed in a vehicle for administration) and cannot swallow a tablet.</li> </ul>
<b>Cautions including any relevant action to be taken</b>	<p>Ensure that patients considered unsuitable for inclusion are promptly referred to their prescriber for further advice.</p>
<b>Special considerations for specific populations of patients</b>	<p>Switching the preparation (including different manufacturer) of the drug requires caution in certain patients who are considered at risk of deterioration due to the <b>nocebo</b> effect whereby patients believe that the exact preparation (including different manufacturer) of the drug is critical to their response.</p> <p>Patients considered unstable or at higher risk need to be referred back to their prescriber promptly for further advice.</p>
<b>Action to be taken if the patient is excluded</b>	<p>If a patient does not meet the criteria within this SSP then they should be referred back to their prescriber promptly.</p>
<b>Action to be taken if the patient or carer declines the supply</b>	<p>If a patient/carer declines to receive medicine under this SSP then they should be referred back to their prescriber promptly.</p>

<b>Valid from:</b>	23 December 2019
<b>Expiry date:</b>	23 March 2020
<b>Reference number:</b>	SSP04
<b>Version number:</b>	1

**Any queries regarding the content of this SSP which was issued by the Secretary of State for Health and Social Care, should be addressed to NHS Prescription Services.**

You can get in contact by:

**Email:** [nhsbsa.prescriptionservices@nhsbsa.nhs.uk](mailto:nhsbsa.prescriptionservices@nhsbsa.nhs.uk)

**Telephone:** 0300 330 1349

**Textphone:** 18001 0300 330 1349

You can also write to us at:

<b>Newcastle</b>	<b>Middlebrook</b>	<b>Wakefield</b>
NHS Prescription Services Bridge House 152 Pilgrim Street Newcastle upon Tyne NE1 6SN	NHS Prescription Services Ridgway House Northgate Close Middlebrook Horwich Bolton BL6 6PQ	NHS Prescription Services 4th Floor Wakefield House Borough Road Wakefield WF1 3UB

### Change history


<b>Version number</b>	<b>Change details</b>	<b>Date</b>

## 2. Conditions under which this Serious Shortage Protocol (SSP) will operate

- The decision to supply any medicine under this protocol rests with the individual registered pharmacist who must abide by the protocol.
- Whilst pharmacy staff may support the dispensing process of the protocol, this must be carried out under the supervision of the registered pharmacist.
- Pharmacists using this SSP must ensure that it is only used within its authorised dates and within the criteria set out within the SSP. Pharmacists must check that

they are using the current version of the SSP, particularly when referring to a hard copy version. Amendments may become necessary prior to the published expiry date. Current versions of SSP templates can be found at <https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/serious-shortage-protocols-ssps>.

- Users must not alter, amend or add to the content of this document; such action will invalidate the SSP.

<b>Ministerial ratification by:</b>			
<b>Name</b>	<b>Position</b>	<b>Signature</b>	<b>Date</b>
Nicola Blackwood	Parliamentary Under Secretary of State for Innovation		20/12/2019